About: To screen or not to screen women for Group B Streptococcus (Streptococcus agalactiae) to prevent early onset sepsis in newborns: recent advances in the unresolved debate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: To screen or not to screen women for Group B Streptococcus (Streptococcus agalactiae) to prevent early onset sepsis in newborns: recent advances in the unresolved debate Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	To screen or not to screen women for Group B Streptococcus (Streptococcus agalactiae) to prevent early onset sepsis in newborns: recent advances in the unresolved debate
Creator	Khanna, Priya Rao, Guduru
Source	Medline; PMC
abstract	Streptococcus agalactiae, also known as Group B streptococcus (GBS) is the commonest cause of early onset sepsis in newborns in developed high-income countries. Intrapartum antimicrobial (antibiotic) prophylaxis (IAP) is recognized to be highly effective in preventing early onset Group B sepsis (EOGBS) in newborns. The key controversy is about the strategy that should be used to identify mothers who should receive IAP. There are two strategies that are followed in developed countries: screening-based or risk-factor-based identification of women requiring IAP. The debate regarding which of the two approaches is better has intensified in the recent years with concerns about antimicrobial resistance, effect on newborn’s microbiome and other adverse effects. In this review, we have discussed some of the key research papers published in the period 2015–2019 that have addressed the relative merits and disadvantages of screening versus risk-factor-based identification of women requiring IAP. Although screening-based IAP appears to be more efficacious than risk-based IAP, IAP-based prevention has several limitations including ineffectiveness in prevention of late-onset GBS infection in babies, premature and still births, impact of IAP on neonatal microbiota, emergence of antimicrobial resistance and difficulties in implementing IAP-based strategies in middle and low income countries. Alternative strategies, principally maternal immunization against GBS would circumvent use of IAP. However, no licensed vaccines are currently available for use.
has issue date	2020-07-13(xsd:dateTime)
bibo:doi	10.1177/2049936120942424
bibo:pmid	32704370
has license	cc-by-nc
sha1sum (hex)	2754417d4d5968ec32e9632160ba166c0ccf404c
schema:url	https://doi.org/10.1177/2049936120942424
resource representing a document's title	To screen or not to screen women for Group B Streptococcus (Streptococcus agalactiae) to prevent early onset sepsis in newborns: recent advances in the unresolved debate
has PubMed Central identifier	PMC7361483
has PubMed identifier	32704370
schema:publication	Ther Adv Infect Dis
resource representing a document's body	covid:2754417d4d5968ec32e9632160ba166c0ccf404c#body_text
is schema:about of	named entity 'IAP' named entity 'newborns' named entity 'Group B' named entity 'high-income countries' named entity 'IAP' named entity 'DIFFICULTIES' named entity 'FOLLOWED' named entity 'ONSET' named entity 'NEWBORN' named entity 'NEWBORNS' named entity 'impact' named entity 'infection' named entity 'IAP' named entity 'IAP' named entity 'onset' named entity 'There' named entity 'identification' named entity 'emergence' named entity 'antimicrobial' named entity 'prophylaxis' named entity 'early' named entity 'IAP' named entity 'antibiotic' named entity 'infection' named entity 'antimicrobial resistance' named entity 'low income countries' named entity 'GBS' named entity 'vaccines' named entity 'intensified' named entity 'CDC' named entity 'developed countries' named entity 'GBS' named entity 'ampicillin' named entity 'GBS' named entity 'systematic review' named entity 'antibiotic prophylaxis' named entity 'Group B streptococcus' named entity 'national guidelines' named entity 'GBS' named entity 'pregnant women' named entity 'National Institute of Health Research' named entity 'anaphylactic reaction' named entity 'penicillin' named entity 'GBS' named entity 'observational studies' named entity 'randomised trials' named entity 'vaccines' named entity 'GBS' named entity 'adverse effects' named entity 'risk factors' named entity '21%' named entity 'penicillin-resistant' named entity 'rupture of membranes' named entity 'allergic' named entity 'Streptococcus agalactiae' named entity 'anaphylaxis' named entity 'NAATs' named entity 'vaccine' named entity 'GBS' named entity 'GBS' named entity 'adverse effects' named entity 'Obstetric' named entity 'GBS' named entity 'Africa' named entity 'neonatal' named entity 'infection' named entity 'relative merits' named entity 'penicillin' named entity 'bacteriuria' named entity 'sub-Saharan Africa' named entity 'rupture of membranes' named entity 'penicillin' named entity 'GBS' named entity 'antibiotic' named entity 'pregnant women' named entity 'GBS' named entity 'treatment options' named entity 'NIHR' named entity 'GBS' named entity 'antibiotic susceptibility'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software